Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 19/20 | 1.00 |
| ▸ | BRAF | P15056 | 6/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | ARAF | P10398 | 1/20 | 0.75 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.75 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566486 | 1.00 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL29566614 | 0.94 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL29611055 | 0.94 | RAF1 (0.89) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL24312156 | 0.94 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL29610545 | 0.93 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL24312200 | 0.93 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL24312194 | 0.92 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL29566617 | 0.92 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL24312191 | 0.92 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL29567095 | 0.92 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11377431-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022081469-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885PDGFRB 538/4885 |
| US-11746095-B2 | Inhibtors of RAF kinases | RAF1, BRAF, ARAF | RAF1 1/4885BRAF 2/4885PDGFRB 542/4885 |
| US-11377431-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885PDGFRB 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.